BOSTON--(BUSINESS WIRE)--Vision Medicines, Inc., a privately-held clinical-stage biopharmaceutical company committed to developing innovative therapies for patients suffering from retinal degeneration diseases, announced that the Foundation Fighting Blindness will collaborate with Vision Medicines in Stargardt disease and co-fund development of VM200 through clinical proof-of-concept to help advance this novel program. Vision Medicines has an exclusive worldwide license for VM200 from Case Western Reserve University. VM200 is a preclinical, oral small molecule drug candidate for the treatment of Stargardt disease, an orphan disease that leads to legal blindness.
Help employers find you! Check out all the jobs and post your resume.
